Navigation Links
Intarcia Therapeutics Appoints Gino Santini To Its Board Of Directors
Date:7/26/2013

nded periods of time.

Data from Intarcia's ITCA 650 Phase 2 program have demonstrated significant and sustained reductions in HbA1c and body weight over 48 weeks of treatment with a marked reduction in the GI adverse events typically associated with the self-injection products in this class. ITCA 650 is an investigational new therapy and is not currently approved by any regulatory authority. Exenatide, the active agent in ITCA 650, is a glucagon-like peptide-1 (GLP-1) receptor agonist currently marketed globally as twice-daily and once-weekly self-injection therapies for type 2 diabetes. Upon approval, ITCA 650 would represent the first injection-free GLP-1 therapy that can deliver a full year of treatment from a single minipump placement. Intarcia's robust intellectual property portfolio protects ITCA 650 through 2031.

About Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. is a biopharmaceutical company developing therapies to enhance treatment outcomes by optimizing and improving the efficacy, continuous administration and tolerability of drug therapies. In addition, delivering medicines just once or twice yearly virtually ensures patient adherence and compliance, which is very poor in most chronic diseases. Intarcia's drug development expertise and competitive edge are demonstrated by its abilities to stabilize proteins and peptides at above-body temperature and to deliver them in a constant and consistent manner via Intarcia's proprietary technology platform. Intarcia is pursuing a Phase 3-stage development program for type 2 diabetes and has additional programs ongoing for weight regulation to control obesity. For more information on the Company, please visit www.intarcia.com.

Intarcia and its logo are registered trademarks of Intarcia Therapeutics, Inc.


'/>"/>
SOURCE Intarcia Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Intarcia Appoints Owen Hughes Chief Business Officer and Head of Corporate Development
2. Intarcia Enrolls First Patients in "FREEDOM" Global Phase 3 Program for ITCA 650 in Type 2 Diabetes
3. Intarcia Supports American Diabetes Association Call For Independent Review Of Incretin-Based Therapies
4. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
5. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
6. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
7. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
8. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
9. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
10. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
11. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... Feb. 27, 2015  Uroplasty, Inc. (NASDAQ: UPI ... markets innovative proprietary products to treat voiding dysfunctions, today ... ROTH Conference on Tuesday, March 10, 2015. Rob ... , Chief Financial Officer, will present at 4:00 p.m. ... at the conference at the Ritz Carlton in ...
(Date:2/26/2015)... -- Finesse expands office in Leicester, United Kingdom ... of its operations in Leicester , ... for customers is expected shortly afterward. With ... the current office, the new premises will double the ... Finesse to bring on more service personnel. The new ...
(Date:2/26/2015)... , Feb. 26, 2015  Today the ... The psychological and physical side effects of pain ... opioid painkillers, such as Vicodin and Oxycontin, are safer ... Americans overdose on prescription painkillers than on heroin and ... and CEO of NSC. "Yet, these medications are marketed ...
Breaking Medicine Technology:Uroplasty to Participate in the 27th Annual ROTH Conference 2New Finesse Office in United Kingdom 2National Safety Council: Opioid prescription painkillers have hidden, deadly side effects 2
... NEW YORK, Oct. 1 Keryx Biopharmaceuticals,Inc. (Nasdaq: ... the,Company,s President, will present an overview of the Company,s ... Growth Stock,Conference in New York City. Dr. Henderson,s presentation ... ET. Dr. Henderson,s presentation will be webcast live ...
... -Two 48-week Superiority Studies versus Hepsera(R) in Patients with Chronic ... Hepatitis B-,-Studies will also Assess Clevudine,s ... ... Pharmasset, Inc.,(Nasdaq: VRUS ) has commenced dosing in Phase 3 registration clinical trials,of clevudine ...
Cached Medicine Technology:Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference 2Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV 2Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV 3Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV 4Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV 5
(Date:2/28/2015)... Gerald “Solutionman” Haman surveyed over 10,000 ... to innovative thinking. “The #1 block was lack ... tools,” reports Haman, who created the Thinkubator Innovation Studio ... felt that they did not have enough time for ... to stimulate innovation. , Solutionman’s monthly “Accelerating Innovation Training” ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 March—also ... good time to remind ourselves and others that ... say Atlantic NeuroSurgical Specialists (ANS). , Concussions are ... account for 75% of TBIs. There are 1.6-3.8 ... may sound benign, but it is a brain ...
(Date:2/28/2015)... 2015 A study out of the ... therapy procedure for the treatment of a hereditary ocular ... Authored by Dr. Robert MacLaren, professor of ophthalmology ... Lancet Medical Journal on January 16, 2014 , the ... genetic disorder that mostly affects men and leads to ...
(Date:2/28/2015)... February 28, 2015 National ... outsourced sales, marketing and supply chain management for ... Botanicals, is bringing its award winning solutions for ... Botanicals’ products are specifically created to combat thinning-damaged ... BIOTA is committed to marrying science with nature ...
(Date:2/28/2015)... AZ (PRWEB) February 28, 2015 Kaylie ... and alcohol treatment center , and current student obtaining ... University, has implemented a weekly forum in psychoeducation on ... school in Flagstaff, AZ as part of her studies. ... big need for support and counseling at the high ...
Breaking Medicine News(10 mins):Health News:New Survey Reveals “Lack of Time” Is the Number #1 Barrier to Innovative Thinking 2Health News:New Survey Reveals “Lack of Time” Is the Number #1 Barrier to Innovative Thinking 3Health News:Atlantic NeuroSurgical Specialists (ANS) Focus on National Brain Injury Awareness Month to Educate the General Public on Head Trauma 2Health News:Atlantic NeuroSurgical Specialists (ANS) Focus on National Brain Injury Awareness Month to Educate the General Public on Head Trauma 3Health News:New Gene Therapy Procedure Could Hold Key to Preventing Blindness for Certain Patients 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 3Health News:Staff at Arizona Drug Addiction Treatment Center Starts Teen Sobriety Support Group at Local High School 2
... test the drug manufactured by German pharmaceutical company TeGenero by ... which was designed to treat rheumatoid arthritis, leukaemia and multiple ... six men who fell seriously ill after taking part in ... like his brain was on fire. Student Nav Modi, 24, ...
... suggests that thinking that you are strong and muscles are ... Hull University research team which asked 30 subjects to do ... focused on what the muscles were doing. ,The ... which monitored levels of electrical activity in their biceps and ...
... a news study it has been shown that babies who ... have the much feared consequences and is safe. The way ... theory was researched and assessed by unconnected Nottingham researchers to ... was pioneered by controversial Stoke-based paediatrician Professor David Southall. ...
... alcohol intake seems to question the earlier studies that ... drinkers, as compared to abstainers or heavy drinkers. ... mistake in the perception of who “abstainers” are, when ... PhD, emerita professor at the University of California, San ...
... 7-day old baby was charred to death due to a short ... their joy and hopes. The incubator in which the baby was ... incident had happened due to negligence of the hospital staff while ... were saved due to prompt action of the medical staff who ...
... to the tune of ?4m or more will be allocated ... spending should take care of containing// the unhealthy trend, atleast ... up by almost 50%. ,A senior medical post ... with suicidal tendencies, according to Mr Woodward. To enable this ...
Cached Medicine News:Health News:High Spirits :Second Thoughts on the Mini Pegs 2Health News:The Face Of Indian Health Care: A World Health Day Evaluation 2Health News:The Face Of Indian Health Care: A World Health Day Evaluation 3Health News:The Face Of Indian Health Care: A World Health Day Evaluation 4
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: